BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 21898683)

  • 1. Concise review: managing genotoxicity in the therapeutic modification of stem cells.
    Baum C; Modlich U; Göhring G; Schlegelberger B
    Stem Cells; 2011 Oct; 29(10):1479-84. PubMed ID: 21898683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking.
    Kustikova O; Fehse B; Modlich U; Yang M; Düllmann J; Kamino K; von Neuhoff N; Schlegelberger B; Li Z; Baum C
    Science; 2005 May; 308(5725):1171-4. PubMed ID: 15905401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CTF/NF1 transcription factors act as potent genetic insulators for integrating gene transfer vectors.
    Gaussin A; Modlich U; Bauche C; Niederländer NJ; Schambach A; Duros C; Artus A; Baum C; Cohen-Haguenauer O; Mermod N
    Gene Ther; 2012 Jan; 19(1):15-24. PubMed ID: 21562592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insertional mutagenesis in gene therapy and stem cell biology.
    Baum C
    Curr Opin Hematol; 2007 Jul; 14(4):337-42. PubMed ID: 17534158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insertional mutagenesis and clonal dominance: biological and statistical considerations.
    Fehse B; Roeder I
    Gene Ther; 2008 Jan; 15(2):143-53. PubMed ID: 17972922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The genomic risk of somatic gene therapy.
    Kustikova O; Brugman M; Baum C
    Semin Cancer Biol; 2010 Aug; 20(4):269-78. PubMed ID: 20600920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.
    Hacein-Bey-Abina S; Von Kalle C; Schmidt M; McCormack MP; Wulffraat N; Leboulch P; Lim A; Osborne CS; Pawliuk R; Morillon E; Sorensen R; Forster A; Fraser P; Cohen JI; de Saint Basile G; Alexander I; Wintergerst U; Frebourg T; Aurias A; Stoppa-Lyonnet D; Romana S; Radford-Weiss I; Gross F; Valensi F; Delabesse E; Macintyre E; Sigaux F; Soulier J; Leiva LE; Wissler M; Prinz C; Rabbitts TH; Le Deist F; Fischer A; Cavazzana-Calvo M
    Science; 2003 Oct; 302(5644):415-9. PubMed ID: 14564000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms of leukemogenesis by AML1/EVI-1.
    Mitani K
    Oncogene; 2004 May; 23(24):4263-9. PubMed ID: 15156182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zebrafish scl functions independently in hematopoietic and endothelial development.
    Dooley KA; Davidson AJ; Zon LI
    Dev Biol; 2005 Jan; 277(2):522-36. PubMed ID: 15617691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of Runx1/AML1 and Evi-1 in the regulation of hematopoietic stem cells.
    Kumano K; Kurokawa M
    J Cell Physiol; 2010 Feb; 222(2):282-5. PubMed ID: 19847803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insertional mutagenesis and transformation of hematopoietic stem cells.
    Ihle JN; Morishita K; Matsugi T; Bartholomew C
    Prog Clin Biol Res; 1990; 352():329-37. PubMed ID: 2169632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress toward the genetic treatment of the beta-thalassemias.
    Sadelain M; Lisowski L; Samakoglu S; Rivella S; May C; Riviere I
    Ann N Y Acad Sci; 2005; 1054():78-91. PubMed ID: 16339654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concise review: The magic act of generating induced pluripotent stem cells: many rabbits in the hat.
    Mostoslavsky G
    Stem Cells; 2012 Jan; 30(1):28-32. PubMed ID: 21948613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotoxicity of retroviral integration in hematopoietic cells.
    Nienhuis AW; Dunbar CE; Sorrentino BP
    Mol Ther; 2006 Jun; 13(6):1031-49. PubMed ID: 16624621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induced pluripotent stem cells expressing elevated levels of sox-2, oct-4, and klf-4 are severely reduced in their differentiation from mesodermal to hematopoietic progenitor cells.
    Seiler K; Soroush Noghabi M; Karjalainen K; Hummel M; Melchers F; Tsuneto M
    Stem Cells Dev; 2011 Jul; 20(7):1131-42. PubMed ID: 21348597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation primary response genes and proto-oncogenes as positive and negative regulators of terminal hematopoietic cell differentiation.
    Liebermann DA; Hoffman B
    Stem Cells; 1994 Jul; 12(4):352-69. PubMed ID: 7951003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enforced TAL-1 expression stimulates primitive, erythroid and megakaryocytic progenitors but blocks the granulopoietic differentiation program.
    Valtieri M; Tocci A; Gabbianelli M; Luchetti L; Masella B; Vitelli L; Botta R; Testa U; Condorelli GL; Peschle C
    Cancer Res; 1998 Feb; 58(3):562-9. PubMed ID: 9458106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells.
    Zhou W; Freed CR
    Stem Cells; 2009 Nov; 27(11):2667-74. PubMed ID: 19697349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chance or necessity? Insertional mutagenesis in gene therapy and its consequences.
    Baum C; von Kalle C; Staal FJ; Li Z; Fehse B; Schmidt M; Weerkamp F; Karlsson S; Wagemaker G; Williams DA
    Mol Ther; 2004 Jan; 9(1):5-13. PubMed ID: 14741772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulating quiescence: new insights into hematopoietic stem cell biology.
    Passegué E; Wagers AJ
    Dev Cell; 2006 Apr; 10(4):415-7. PubMed ID: 16580989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.